Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

<p>Glioblastoma patient characteristics (DFCI)</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Joseph Toker (15399882) (author)
Rannpháirtithe:	J. Bryan Iorgulescu (15030477) (author), Alexander L. Ling (15399885) (author), Genaro R. Villa (15399888) (author), Josephina A.M.A. Gadet (15399891) (author), Laxmi Parida (15112564) (author), Gad Getz (14945542) (author), Catherine J. Wu (14944480) (author), David A. Reardon (15043854) (author), E. Antonio Chiocca (15399894) (author), Marco Mineo (15399897) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers CNS Cancers Gliomas, Glioblastomas Immunotherapy Checkpoint blockade Skin Cancers Melanoma
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
de réir: Isha Mondal (16721699)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
de réir: Francesca Orzan (15055579)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
de réir: Francesca Orzan (15055579)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
de réir: Francesca Orzan (15055579)
Foilsithe / Cruthaithe: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
de réir: Michael Kilian (16697663)
Foilsithe / Cruthaithe: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
de réir: Michael Kilian (16697663)
Foilsithe / Cruthaithe: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
de réir: Michael Kilian (16697663)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
de réir: Defne Bayik (14961098)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
de réir: Qingsheng Xu (17078830)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
de réir: Qingsheng Xu (17078830)
Foilsithe / Cruthaithe: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
de réir: Reza Mirzaei (15306062)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
de réir: Reza Mirzaei (15306062)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
de réir: Reza Mirzaei (15306062)
Foilsithe / Cruthaithe: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
de réir: Bachchu Lal (17141949)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
de réir: William Kelly (15439117)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
de réir: William Kelly (15439117)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_tef6gksfbcpbifs09kkc2ad3dc